Terms: = Endocrine gland cancer AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169
251 results:
1. Identification and validation of an anoikis-related genes signature for prognostic implication in papillary thyroid cancer.
Zhao R; Lu Y; Wan Z; Qiao P; Yang L; Zhang Y; Huang S; Chen X
Aging (Albany NY); 2024 Apr; 16(8):7405-7425. PubMed ID: 38663918
[TBL] [Abstract] [Full Text] [Related]
2. Iron overload increases the sensitivity of endometriosis stromal cells to ferroptosis via a PRC2-independent function of ezh2.
Luo Y; Li L; Hu Q; Zhang Z; Liu F; Peng Y; Zou Y; Chen L
Int J Biochem Cell Biol; 2024 Apr; 169():106553. PubMed ID: 38417568
[TBL] [Abstract] [Full Text] [Related]
3. ezh2-mediated development of therapeutic resistance in cancer.
Kaur P; Shankar E; Gupta S
Cancer Lett; 2024 Apr; 586():216706. PubMed ID: 38331087
[TBL] [Abstract] [Full Text] [Related]
4. MAPRE3 as an epigenetic target of ezh2 restricts ovarian cancer proliferation in vitro and in vivo.
Zhang Y; Liu F; Zheng J; Jiang K; Ai H; Liu L; Mao D
Exp Cell Res; 2024 Feb; 435(1):113913. PubMed ID: 38199479
[TBL] [Abstract] [Full Text] [Related]
5. Drug-induced inhibition of HMGA and ezh2 activity as a possible therapy for anaplastic thyroid carcinoma.
De Martino M; Pellecchia S; Decaussin-Petrucci M; Testa D; Meireles Da Costa N; Pallante P; Chieffi P; Fusco A; Esposito F
Cell Cycle; 2023; 22(23-24):2552-2565. PubMed ID: 38165007
[TBL] [Abstract] [Full Text] [Related]
6. Underrepresentation of racial and ethnic minority groups in gynecologic oncology: An analysis of over 250 trials.
Richardson MT; Barry D; Steinberg JR; Thirunavu V; Strom DE; Holder K; Zhang N; Turner BE; Magnani CJ; Weeks BT; Young AMP; Lu CF; Wolgemuth TR; Laasiri N; Squires NA; Anderson JN; Karlan BY; Chan JK; Kapp DS; Roque DR; Salani R
Gynecol Oncol; 2024 Feb; 181():1-7. PubMed ID: 38096673
[TBL] [Abstract] [Full Text] [Related]
7. A clinically useful and biologically informative genomic classifier for papillary thyroid cancer.
Craig S; Stretch C; Farshidfar F; Sheka D; Alabi N; Siddiqui A; Kopciuk K; Park YJ; Khalil M; Khan F; Harvey A; Bathe OF
Front Endocrinol (Lausanne); 2023; 14():1220617. PubMed ID: 37772080
[TBL] [Abstract] [Full Text] [Related]
8. ezh2 Contributes to Anoikis Resistance and Promotes Epithelial Ovarian cancer Peritoneal Metastasis by Regulating m6A.
Wang SH; Liu L; Bao KY; Zhang YF; Wang WW; Du S; Jia NE; Suo S; Cai J; Guo JF; Lv G
Curr Med Sci; 2023 Aug; 43(4):794-802. PubMed ID: 37498408
[TBL] [Abstract] [Full Text] [Related]
9. Exploiting an epigenetic switch in adrenal cancer.
Ferrarelli LK
Sci Signal; 2023 Jul; 16(794):eadj7203. PubMed ID: 37463243
[TBL] [Abstract] [Full Text] [Related]
10. Long non-coding RNA SNHG17 contributes to the progression of pancreatic adenocarcinoma by modulating miR-32-5p/ezh2/STAT3 signaling.
Ying L; Wang J; Feng J; Wu Z
Mol Biol Rep; 2023 Jul; 50(7):5941-5947. PubMed ID: 37253918
[TBL] [Abstract] [Full Text] [Related]
11. ezh2 mediated metabolic rewiring promotes tumor growth independently of histone methyltransferase activity in ovarian cancer.
Chen J; Hong JH; Huang Y; Liu S; Yin J; Deng P; Sun Y; Yu Z; Zeng X; Xiao R; Chan JY; Guan P; Wang Y; Wang P; Liu L; Wen S; Yu Q; Ong CK; Teh BT; Xiong Y; Tan J
Mol Cancer; 2023 May; 22(1):85. PubMed ID: 37210576
[TBL] [Abstract] [Full Text] [Related]
12. Pharmacological inhibition of ezh2 using a covalent inhibitor suppresses human ovarian cancer cell migration and invasion.
Shi L; Zhang Q; Zhu S; Tang Q; Chen X; Lan R; Wang N; Zhu Y
Mol Cell Biochem; 2024 Apr; 479(4):831-841. PubMed ID: 37199893
[TBL] [Abstract] [Full Text] [Related]
13. ezh2 regulates pancreatic cancer cells through E2F1, GLI1, CDK3, and Mcm4.
Li H; Wang H; Cui Y; Jiang W; Zhan H; Feng L; Gao M; Zhao K; Zhang L; Xie X; Zhao N; Li Y; Liu P
Hereditas; 2023 May; 160(1):23. PubMed ID: 37198697
[TBL] [Abstract] [Full Text] [Related]
14. Modulation of ezh2 Activity Induces an Antitumoral Effect and Cell Redifferentiation in Anaplastic Thyroid cancer.
de Mello DC; Saito KC; Cristovão MM; Kimura ET; Fuziwara CS
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175580
[TBL] [Abstract] [Full Text] [Related]
15. β-Catenin-Driven Differentiation Is a Tissue-Specific Epigenetic Vulnerability in Adrenal cancer.
Mohan DR; Borges KS; Finco I; LaPensee CR; Rege J; Solon AL; Little DW; Else T; Almeida MQ; Dang D; Haggerty-Skeans J; Apfelbaum AA; Vinco M; Wakamatsu A; Mariani BMP; Amorim LC; Latronico AC; Mendonca BB; Zerbini MCN; Lawlor ER; Ohi R; Auchus RJ; Rainey WE; Marie SKN; Giordano TJ; Venneti S; Fragoso MCBV; Breault DT; Lerario AM; Hammer GD
Cancer Res; 2023 Jul; 83(13):2123-2141. PubMed ID: 37129912
[TBL] [Abstract] [Full Text] [Related]
16. LncRNA SLC25A21-AS1 increases the chemosensitivity and inhibits the progression of ovarian cancer by upregulating the expression of KCNK4.
Huang K; Chen X; Geng Z; Xiong X; Cong Y; Pan X; Liu S; Ge L; Xu J; Jia X
Funct Integr Genomics; 2023 Mar; 23(2):110. PubMed ID: 36995496
[TBL] [Abstract] [Full Text] [Related]
17. A case of vasculogenic mesenchymal tumor in the mediastinum: whole-exome sequencing reveals origin from pre-existing germ cell tumor.
Fujii H; Yamada Y; Yamamura K; Ishida Y; Tsujimura M; Matsumoto K; Tanaka S; Date H; Nishikawa T; Yoshida Y; Kashima J; Yatabe Y; Ogawa S; Marx A; Ulbright TM; Haga H
Virchows Arch; 2023 May; 482(5):923-927. PubMed ID: 36943470
[TBL] [Abstract] [Full Text] [Related]
18. Validation of ezh2 Inhibitor Efficiency in Anaplastic Thyroid Carcinoma Cell Lines.
Nakayama H; Saito N; Kasajima R; Suganuma N; Rino Y; Masudo K; Yamazaki H; Toda S; Sekihara K; Iwasaki H; Hoshino D
Anticancer Res; 2023 Mar; 43(3):1073-1077. PubMed ID: 36854530
[TBL] [Abstract] [Full Text] [Related]
19. Differential effects of the LncRNA RNF157-AS1 on epithelial ovarian cancer cells through suppression of DIRAS3- and ULK1-mediated autophagy.
Xu P; Xu S; Pan H; Dai C; Xu Y; Wang L; Cong Y; Zhang H; Cao J; Ge L; Jia X
Cell Death Dis; 2023 Feb; 14(2):140. PubMed ID: 36805591
[TBL] [Abstract] [Full Text] [Related]
20. The epigenetic ezh2/H3K27me3 axis modulates lactotroph tumor cell proliferation.
Zlocowski N; Sosa LDV; De la Cruz-Thea B; Guido CB; Martín MG; Mukdsi JH; Torres AI; Petiti JP
J Endocrinol; 2023 May; 257(2):. PubMed ID: 36786578
[TBL] [Abstract] [Full Text] [Related]
[Next]
